Italian gene therapy player draws new investor from China for its answer to CAR-T relapses

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 10, 2019 at 11:52 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,730
    Likes Received:
    3
    via So you’ve been treated with one of the new-age cancer therapies. What do you do if there’s a relapse and the tumors returns?

    Genenta Science launched four years ago out of Milan in part to answer that question, and today they received $14.4 million in round three funding that will propel their unique gene therapy through Phase I/II trials for multiple myeloma and glioblastoma.

    article source